BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.18B +49.8% |
| Revenue (ttm) | 940.61M +68.7% |
| Net Income | -384.67M |
| EPS | -1.68 |
| Shares Out | 255.54M |
| PE Ratio | n/a |
| Forward PE | 17.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,307,844 |
| Open | 8.27 |
| Previous Close | 8.29 |
| Day's Range | 8.27 - 8.60 |
| 52-Week Range | 6.00 - 11.22 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 20.73 (+142.46%) |
| Est. Earnings | Nov 2, 2026 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price target is $20.73, which is an increase of 142.46% from the latest price.
News
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd...
BioCryst price target raised to $13 from $12 at JPMorgan
JPMorgan raised the firm’s price target on BioCryst (BCRX) to $13 from $12 and keeps a Neutral rating on the shares. The firm updated the company’s model ahead of the…
BioCryst Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A shift to external innovation and strategic acquisitions is driving pipeline expansion and profitability, with ORLADEYO and navenibart positioned for complementary growth. The company targets rare diseases with strong science and maintains a strict focus on sustained profitability.
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded BioCryst (BCRX) to Sector Perform from Outperform with a price target of $11, down from $13. BioCryst faces a more challenging near-term outlook as stronger-than-expected Pharva...
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded BioCryst (BCRX) to Sector Perform from Outperform with a price target of $11, down from $13.
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Globa...
BioCryst is profitable. Now it wants to buy more rare disease drugs
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize b...
BioCryst announces Japan MHLW marketing approval for Orladeyo
BioCryst (BCRX) announced that Japan’s Ministry of Health, Labor and Welfare has granted marketing approval for once-daily Orladeyo for prophylactic therapy in pediatric patients with hereditary angio...
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
BioCryst price target lowered to $20 from $21 at Wedbush
Wedbush lowered the firm’s price target on BioCryst (BCRX) to $20 from $21 and keeps an Outperform rating on the shares. Overall, a solid quarter of execution for BioCryst, with…
BioCryst price target lowered to $13 from $14 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on BioCryst (BCRX) to $13 from $14 and keeps an Outperform rating on the shares. BioCryst reported a slight miss…
BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 45% revenue growth year-over-year, strong ORLADEYO demand, and a successful pediatric launch. Cost discipline and external innovation strategy improved profitability and cash position, with raised revenue guidance for 2026.
BioCryst Pharmaceuticals Earnings release: Q2 2026
BioCryst Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BioCryst Pharmaceuticals Slides: Q2 2026
BioCryst Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
BioCryst Pharmaceuticals Quarterly report: Q2 2026
BioCryst Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
BioCryst Reports Second Quarter 2026 Financial Results
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 O...
BioCryst to Report Second Quarter 2026 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on ...
BioCryst appoints David Jenkins as chief scientific officer
BioCryst (BCRX) announced the appointment of David Jenkins to the newly created position of chief scientific officer, effective immediately, reporting to Sandeep Menon, chief research and development ...
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD...
BioCryst resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of BioCryst (BCRX) with a Neutral rating and $12 price target The stock’s path to upside is heavily dependent on the navenibart launch, the analyst tells investors…
BioCryst price target raised to $14 from $13 at RBC Capital
RBC Capital raised the firm’s price target on BioCryst (BCRX) to $14 from $13 and keeps an Outperform rating on the shares as part of a broader research note previewing…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n...
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on BioCryst (BCRX) to $29 from $27 and keeps an Overweight rating on the shares. The long-term commercial outlook for a Q6M hereditary…
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to b...
BioCryst to discontinue internal discovery programs, close Alabama facility
BioCryst (BCRX) announced that it will discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026. Following a strategi...